Kelun Highlights First-Line Plans For Merck-Partnered Trop2 ADC

 
• By Dexter Jie Yan
  
first line treatment
1L treatment of EGFR-wild type NSCLC takes center stage in Kelun/Merck's plan for Trop2-targeting ADC • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia